<p>Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis</p>

Abstract

Purpose: Gliomas are the most common primary malignant neoplasms of the central nervous system. Secreted phospholipases A2 (sPLA2s) are known to play an important role in various physiological processes, including bioactive lipid production, defense mechanisms, and cell signaling. However, their roles and clinical importance in gliomas remain unclear. Patients and methods: In this study, we analyzed the association between the expression of various sPLA2-encoding genes and the clinicopathology of gliomas, using the data of 1047 patients obtained from a public database. Immunohistochemical analysis of 82 glioma tissues was also carried out to assess the relationship between phospholipase A2 group V (PLA2G5) protein expression and the World Health Organization (WHO) glioma grades. Results: We found that high PLA2G5 gene expression was associated with unfavorable prognosis in both low-grade and high-grade gliomas. The immunohistochemistry of the 82 glioma tissues further confirmed that PLA2G5 protein expression was dependent on the WHO glioma grade. In addition, we found a correlation between PLA2G5 gene expression and both epithelial–mesenchymal transition and the isocitrate dehydrogenase 1 mutation status in these tumors. Conclusion: Our results indicate that PLA2G5 could be a potential biomarker for predicting poor prognosis in patients with gliomas.

LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR‐134/Myc/ABCC1 axis in glioma

“…Immunohistochemistry was carried out as described previously 19 . The following antibody was used: rabbit polyclonal antibody to MYC (Sangon Biotech).…”

Knockdown lncRNA DLEU1 Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Regulating Autophagy

“…Glioma, accounting for approximately 80% of malignant tumors, is one of the most primary and fatal intracranial tumors ( Jin et al, 2019 ; Wu et al, 2019 ). Despite advances in diagnosis and therapy such as surgical resection followed by adjuvant radiotherapy and chemotherapy, patients with glioblastoma have a median survival time of merely 12–15 months Parsons et al, 2008 ; Mostafa et al, 2016 ).…”

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma

“…For instance, quinacrine (CV-R 0.54) is a known inhibitor of phospholipase A2 (PLA2), an enzyme that hydrolyzes phospholipids into second messengers that regulate cell proliferation, cell migration, and cell survival through binding of G-protein-coupled receptors (Moolenaar et al, 2004). High expression of PLA2 has been associated with poor prognosis and therapy resistance in glioma patients (Wu et al, 2019;Yang and Zhang, 2018). As a second example, the activity of digoxin and digitoxigenin may imply Na + -K+ ATPase (ATP1A1) as a possible target in GBM, or other targets affected by digoxin drugs in GBM cells, such as HIF1alpha and HIF2alpha (Joseph et al, 2015).…”